m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00768)
Target Name Histone deacetylase 4 (HDAC4)
Synonyms
KIAA0288; Histone deacetylase 4; HD4; EC 3.5.1.98
    Click to Show/Hide
Gene Name HDAC4
Chromosomal Location 2q37.3
Family Histone deacetylase family, HD type 2 subfamily
Function
Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Involved in muscle maturation via its interaction with the myocyte enhancer factors such as MEF2A, MEF2C and MEF2D. Involved in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer. Deacetylates HSPA1A and HSPA1B at 'Lys-77' leading to their preferential binding to co-chaperone STUB1.
    Click to Show/Hide
Gene ID 9759
Uniprot ID
HDAC4_HUMAN
HGNC ID
HGNC:14063
Ensembl Gene ID
ENSG00000068024.18
KEGG ID
hsa:9759
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
HDAC4 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
RNA demethylase ALKBH5 (ALKBH5) [ERASER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary ALKBH5 demethylates and stabilizes Hdac4 mRNA. Histone deacetylase 4 (HDAC4) interacts with and deacetylates FoxO3, resulting in a significant increase in FoxO3 expression. These results suggest that ALKBH5 is a potential therapeutic target for neurogenic muscle atrophy.
Target Regulation Up regulation
Responsed Disease Progressive muscular atrophy ICD-11: 8B60.3
 Disease Info 
Pathway Response FoxO signaling pathway hsa04068
In-vivo Model Mice bearing the Alkbh5-floxed allele (Alkbh5 fl/fl , Cyagen) were crossed with transgenic mice expressing Cre recombinase under the control of the Myl1 promoter (Myl1-Cre; Stock No: 024713, The Jackson Laboratory) to generate muscle-specific Alkbh5 knockout mice (Myl1-Cre;Alkbh5 fl/fl ). Littermate Alkbh5fl/fl mice were used as controls. Genotyping by tail DNA and PCR were performed at 4 weeks of age.
Motor neuron disease [ICD-11: 8B60]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary ALKBH5 demethylates and stabilizes Hdac4 mRNA. Histone deacetylase 4 (HDAC4) interacts with and deacetylates FoxO3, resulting in a significant increase in FoxO3 expression. These results suggest that ALKBH5 is a potential therapeutic target for neurogenic muscle atrophy.
Responsed Disease Progressive muscular atrophy [ICD-11: 8B60.3]
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
Target Regulation Up regulation
Pathway Response FoxO signaling pathway hsa04068
In-vivo Model Mice bearing the Alkbh5-floxed allele (Alkbh5 fl/fl , Cyagen) were crossed with transgenic mice expressing Cre recombinase under the control of the Myl1 promoter (Myl1-Cre; Stock No: 024713, The Jackson Laboratory) to generate muscle-specific Alkbh5 knockout mice (Myl1-Cre;Alkbh5 fl/fl ). Littermate Alkbh5fl/fl mice were used as controls. Genotyping by tail DNA and PCR were performed at 4 weeks of age.
References
Ref 1 m(6) A demethylase ALKBH5 drives denervation-induced muscle atrophy by targeting HDAC4 to activate FoxO3 signalling. J Cachexia Sarcopenia Muscle. 2022 Apr;13(2):1210-1223. doi: 10.1002/jcsm.12929. Epub 2022 Feb 9.